JNCI Journal of the National Cancer Institute · 1990 · 25 citations · 0 references
PharmacyOncologyPharmacologyCell TherapyChemotherapyHematologic OncologyAdverse Effects Of ChemotherapyCell Therapy ToxicityChemotherapy Toxicity ManagementCytotoxic ChemotherapyHigh-dose ChemotherapyPulmonary Toxicity ManagementAutologous Stem Cell InfusionAutologous Stem Cell TherapyCancer Therapy-related Pulmonary ToxicityChemotherapy-induced Pulmonary ToxicityCyclophosphamide-based TherapyDrug-induced Lung DiseaseNon-hodgkin Lymphoma TherapyRefractory Solid Tumors
Forty patients with refractory solid tumors or non-Hodgkin's lymphoma were treated with high-dose cyclophosphamide, thiotepa, and carmustine (BCNU), followed by autologous stem cell rescue, in a phase I dose escalation study. The dose-limiting toxic effect was delayed drug-induced pulmonary disease, seen in three patients who received 660-750 mg of BCNU/m2 in combination with cyclophosphamide and thiotepa. The early death rate due to toxic effects was 20%; all deaths were attributed to sepsis or respiratory failure. The overall response rate was 63%. The median time to disease progression was 14 weeks. Although this regimen provided effective cytoreduction, its use in heavily pretreated patients with bulky disease is of limited value.